In China, an NGS‐based companion diagnostic for pemigatinib (Malignant Neoplasms Multi‐Gene Analysis Kit) is being developed in parallel, to be used for identifying patients with cholangiocarcinoma carrying FGFR2 rearrangements who are eligible for pemigatinib treatment. Here, FGFR2 is linked to cholangiocarcinoma.